Asset Details
Do you wish to reserve the book?
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Do you wish to request the book?
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
2015
Overview
Isavuconazole is a new extended-spectrum triazole with activity against yeasts, molds, and dimorphic fungi. It is approved for the treatment of invasive aspergillosis and mucormycosis. Advantages of this triazole include the availability of a water-soluble intravenous formulation, excellent bioavailability of the oral formulation, and predictable pharmacokinetics in adults. A randomized, double-blind comparison clinical trial for treatment of invasive aspergillosis found that the efficacy of isavuconazole was noninferior to that of voriconazole. An open-label trial that studied primary as well as salvage therapy of invasive mucormycosis showed efficacy with isavuconazole that was similar to that reported for amphotericin B and posaconazole. In patients in these studies, as well as in normal volunteers, isavuconazole was well tolerated, appeared to have few serious adverse effects, and had fewer drug–drug interactions than those noted with voriconazole. As clinical experience increases, the role of this new triazole in the treatment of invasive fungal infections will be better defined.
Publisher
Oxford University Press
Subject
Antifungal Agents - adverse effects
/ Antifungal Agents - pharmacokinetics
/ Antifungal Agents - therapeutic use
/ Drug-Related Side Effects and Adverse Reactions
/ Drugs
/ Humans
/ Invasive Pulmonary Aspergillosis - drug therapy
/ Pyridines - pharmacokinetics
/ Randomized Controlled Trials as Topic
/ REVIEWS OF ANTI-INFECTIVE AGENTS
/ Triazoles - pharmacokinetics
/ Yeasts
